首页|复方藜芍片对大鼠原发性三叉神经痛的治疗作用

复方藜芍片对大鼠原发性三叉神经痛的治疗作用

扫码查看
目的 考察复方藜芍片对大鼠原发性三叉神经痛的治疗作用并初步探索相关机制。方法 建立雄性SD大鼠眶下神经压迫术原发性三叉神经痛模型,随机分为模型组、卡马西平组及复方藜芍片低、中、高剂量(420、840、1 680 mg/kg)组,ig给药 28 d;定期测定术侧面部机械痛敏阈值(MWT);ELISA试剂盒检测血清中肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)水平;q-PCR检测三叉神经节中TNF-α、IL-1 β mRNA表达;Western blotting检测三叉神经节中降钙素基因相关肽(CGRP)表达;免疫组化检测大脑纹状体中磷酸化 p38 丝裂原活化蛋白激酶(p-p38 MAPK)表达。结果 术后当天各组大鼠术侧MWT与术前相比均显著下降(P<0。05),大鼠原发性三叉神经痛模型造模成功。复方藜芍片高剂量组MWT值为 19。58,与模型组比较MWT值增加 36。6%(P<0。05),复方藜芍片对原发性三叉神经痛模型大鼠的MWT有显著性改善。与卡马西平组(14。17)相比,复方藜芍片中、高剂量组大鼠MWT均显著性上升(P<0。05)。与模型组相比,复方藜芍片中、高剂量组大鼠血清中TNF-α、IL-1β水平,三叉神经节中TNF-α、IL-1 β mRNA、CGRP以及纹状体中p-p38 MAPK表达均显著下降(P<0。05)。结论 复方藜芍片可对原发性三叉神经痛发挥治疗作用,其机制可能与降低炎症相关因子以及蛋白的表达有关。
Study on Compound Lishao Tablets in treatment of primary trigeminal neuralgia in rats
Objective To investigate the therapeutic effect of Compound Lishao Tablets on primary trigeminal neuralgia in rats and explore the related mechanism.Methods Primary trigeminal neuralgia model established by chronic constriction injury of the infraorbital nerve,and then these rats were randomly divided into model group,carbamazepine group,low-dose Compound Lishao Tablets group,middle-dose Compound Lishao Tablets group,high-dose Compound Lishao Tablets group for 28 d gavage administration.The mechanical pain threshold(MWT)of the operated side was measured regularly,the levels of TNF-α and IL-1β in serum were detected by ELISA kit,the expression of TNF-α and IL-1β mRNA in trigeminal ganglion was detected by q-PCR,the expression of calcitonin gene related peptide(CGRP)in trigeminal ganglion was detected by Western blotting,and the expression of phosphorylated p38 mitogen activated protein kinase(p-p38 MAPK)in cerebral striatum was detected by immunohistochemistry.Results On the day after operation,MWT at the operative side of rats in all groups was significantly decreased compared with that before operation(P<0.05),primary trigeminal neuralgia modeling is successful.The MWT value of Compound Lishao Tablet high-dose group was 19.58,which was increased by 36.6%compared with model group(P<0.05),and Compound Lishao Tablets significantly improved the MWT value of primary trigeminal neuralgia model rats.Compared with the carbamazepine group(14.17),the MWT of rats in the middle-dose Compound Lishao Tablets group and high-dose Compound Lishao Tablets group significantly increased.Compared to the model group,the expression of TNF-α,IL-1β in serum,the level of TNF-α,IL-1β mRNA,CGRP in trigeminal ganglion and the p-p38 MAPK in striatum are significantly decreasing(P<0.05)of middle-dose Compound Lishao Tablets group and high-dose Compound Lishao Tablets group.Conclusion Compound Lishao Tablets can exert therapeutic effects on primary trigeminal neuralgia,and its mechanism may be related to reducing the expression of inflammation related factors and proteins.

Compound Lishao TabletsCarbamazepine Tabletsprimary trigeminal neuralgiaMWTTNF-αIL-1βCGRPp-p38 MAPK

李顺欣、郭姝羽、陈宇翔、郭振宇、贾双赫、李海刚

展开 >

长沙医学院 口腔学院,湖南 长沙 410219

长沙医学院 临床学院,湖南 长沙 410219

长沙医学院 新型药物制剂研发湖南省重点实验室,湖南 长沙 410219

复方藜芍片 卡马西平片 原发性三叉神经痛 机械痛敏阈值 肿瘤坏死因子-α 白细胞介素-1β 降钙素基因相关肽 磷酸化p38丝裂原活化蛋白激酶

国家级大学生创新创业训练计划项目

202110823024

2024

现代药物与临床
天津药物研究院,中国药学会

现代药物与临床

CSTPCD
影响因子:1.179
ISSN:1674-5515
年,卷(期):2024.39(3)
  • 30